2020
DOI: 10.2217/fon-2019-0650
|View full text |Cite
|
Sign up to set email alerts
|

The emerging development of tumor mutational burden in patients with NSCLC

Abstract: Immunocheckpoint inhibitors (ICIs) which target PD-1 and CTLA-4 have dramatically changed the history of non-small-cell lung cancer treatment. Multiple biomarkers especially tumor mutational burden (TMB) have been raised to be potential predictors of response to ICIs. However, great value of TMB has been observed in patients who receive ICIs monotherapy instead of ICIs combination therapy from latest exploratory studies. Thus, the innovative concept of TMB needs to be identified. This study uncovers specific a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(3 citation statements)
references
References 112 publications
0
2
0
1
Order By: Relevance
“…TMB is generally defined as the total number of somatic coding mutations, which is associated with the generation of neoantigens that induce antitumour immunity[ 17 ]. Higher TMB scores are generally associated with durable clinical benefit and improved objective response in tumour immunotherapy, and it can predict immunotherapy efficacy in multiple tumours including NSCLC[ 18 , 19 ]. We calculated the tumour mutation burden of LUAD patients and the result showed the top 15 genes with the highest mutation frequency ( Figure 9(A, B) ).…”
Section: Resultsmentioning
confidence: 99%
“…TMB is generally defined as the total number of somatic coding mutations, which is associated with the generation of neoantigens that induce antitumour immunity[ 17 ]. Higher TMB scores are generally associated with durable clinical benefit and improved objective response in tumour immunotherapy, and it can predict immunotherapy efficacy in multiple tumours including NSCLC[ 18 , 19 ]. We calculated the tumour mutation burden of LUAD patients and the result showed the top 15 genes with the highest mutation frequency ( Figure 9(A, B) ).…”
Section: Resultsmentioning
confidence: 99%
“…Patients with advanced tumors who cannot receive standard treatment may benefit from immunotherapy if they have a high TMB. However, TMB is not unanimously accepted ( 33 , 34 ). The CheckMate 227 study updates OS data and finds that TMB does not predict OS gain.…”
Section: Discussionmentioning
confidence: 99%
“…Porém, problemas pré-analíticos, analíticos e pós-analíticos foram investigados, resultando em pouca sensibilidade e especificidade robusta do PD-L1 IHQ, devendo haver cautela antes da sua implementação. O biomarcador tumor mutacional burden/tumor mutation burden (TMB) é um potencial promissor em PD-1 monoterapia, tendo sido observada uma correlação de TMB alto e resposta clínica a ICIs em ensaios (URUGA; MINO-KENUDSON, 2021;ZHANG et al, 2020).…”
Section: )unclassified